Literature DB >> 8669866

Expression of the CD44 glycoprotein (lymphocyte-homing receptor) in untreated human breast cancer and its relationship to prognostic markers.

M de la Torre1, P Heldin, J Bergh.   

Abstract

CD44 is a cell surface glycoprotein which has been suggested to be associated with aggressive histological features in breast cancer (BC). It has also been implicated in conferring metastatic potential to rat carcinoma cells. The aim of this study was to determine the potential value of CD44 as a prognostic/metastatic marker in BC by means of immunohistochemistry. The expression of the CD44 glycoprotein was investigated in tumours from 52 untreated female patients with BC, using the monoclonal antibody A3D8. 10 samples of normal breast tissue were randomly obtained and also investigated with respect to CD44 expression. DNA ploidy, the S-phase fraction (SPF) and oestrogen-(OR) and progesterone-receptor (PgR) contents in the tumours were determined and together with the prognostic markers of age, tumour size, tumour grade and lymph node status, correlated with CD44 expression in BC. Also, the distribution of CD44 tumour cell expression was compared with expression of the permeability drug resistance glycoprotein (P-gp) in this material. Expression of CD44 on carcinoma cells was observed in 21/52 cases (40%). Capillary endothelial reactivity of the tumours occurred in 42 cases (80%). Non-neoplastic epithelial breast tissue was positive in 2/10 (20%) samples and capillary vessels in 7/10 (70%). Carcinoma CD44 cell expression was not associated with age, tumour size, tumour grade, DNA ploidy, SPF, hormone-receptor contents or lymph node metastases. There was a statistical correlation between CD44 and P-gp expression in breast carcinoma cells which may suggest a connection between adhesion molecules and drug resistance. These findings do not support an association between CD44 expression and adverse prognostic features or lymph node metastases in BC. Capillary CD44 staining was a common feature in BC. There appeared to be an upward regulation in CD44 expression in BC compared with the normal breast tissue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8669866

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Hyaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1).

Authors:  Berit Bernert; Helena Porsch; Paraskevi Heldin
Journal:  J Biol Chem       Date:  2011-10-20       Impact factor: 5.157

Review 2.  CD44 in inflammation and metastasis.

Authors:  J Lesley; R Hyman; N English; J B Catterall; G A Turner
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

3.  Overexpressed human CD44s promotes lung colonization during micrometastasis of murine fibrosarcoma cells: facilitated retention in the lung vasculature.

Authors:  P Kogerman; M S Sy; L A Culp
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

4.  Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells.

Authors:  Ibrahima Youm; Vivek Agrahari; James B Murowchick; Bi-Botti C Youan
Journal:  Pharm Res       Date:  2014-03-19       Impact factor: 4.200

5.  Putative markers for the detection of breast carcinoma cells in blood.

Authors:  E M Eltahir; D S Mallinson; G D Birnie; C Hagan; W D George; A D Purushotham
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

6.  Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.

Authors:  Jhih-Ying Chi; Yu-Wei Hsiao; Chien-Feng Li; Yu-Chih Lo; Zu-Yau Lin; Jhen-Yi Hong; Yang-Ming Liu; Xiu Han; Shao-Ming Wang; Ben-Kuen Chen; Kelvin K Tsai; Ju-Ming Wang
Journal:  Oncotarget       Date:  2015-09-15

7.  Quantitative analysis of multidrug-resistance mdr1 gene expression in head and neck cancer by real-time RT-PCR.

Authors:  Ching-Ping Tseng; Ann-Joy Cheng; Joseph Tung-Chieh Chang; Chin-Hsiao Tseng; Hung-Ming Wang; Chun-Ta Liao; I-How Chen; Kelvin Chingchung Tseng
Journal:  Jpn J Cancer Res       Date:  2002-11

8.  Disruption of the pentraxin 3/CD44 interaction as an efficient therapy for triple-negative breast cancers.

Authors:  Yu-Wei Hsiao; Jhih-Ying Chi; Chien-Feng Li; Lei-Yi Chen; Yi-Ting Chen; Hsin-Yin Liang; Yu-Chih Lo; Jhen-Yi Hong; Chin-Pin Chuu; Liang-Yi Hung; Jyun-Yi Du; Wen-Chang Chang; Ju-Ming Wang
Journal:  Clin Transl Med       Date:  2022-01

9.  Overexpression of CD44 is associated with the occurrence and migration of non-small cell lung cancer.

Authors:  Guanghu Li; Yufei Gao; Yongsheng Cui; Tao Zhang; Rui Cui; Yang Jiang; Jingwei Shi
Journal:  Mol Med Rep       Date:  2016-08-18       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.